Switch theme
Sign up to access all valuation multiples
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe, and the rest of the world.
1977
12.7K+
LTM Revenue $1.6B
LTM EBITDA $289M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Glenmark Pharma has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $289M.
In the most recent fiscal year, Glenmark Pharma achieved revenue of $1.5B and an EBITDA of $245M.
Glenmark Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Glenmark Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.5B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $289M | XXX | $245M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $238M | XXX | $218M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $172M | XXX | $123M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $60.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, Glenmark Pharma's stock price is INR 1753 (or $21).
Glenmark Pharma has current market cap of INR 495B (or $5.8B), and EV of INR 502B (or $5.9B).
See Glenmark Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $5.8B | XXX | XXX | XXX | XXX | $0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, Glenmark Pharma has market cap of $5.8B and EV of $5.9B.
Glenmark Pharma's trades at 3.9x EV/Revenue multiple, and 26.9x EV/EBITDA.
Equity research analysts estimate Glenmark Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Glenmark Pharma has a P/E ratio of 33.7x.
See valuation multiples for Glenmark Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.8B | XXX | $5.8B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 20.3x | XXX | 26.9x | XXX | XXX | XXX |
| EV/EBIT | 24.7x | XXX | 32.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.7x | XXX | 120.7x | XXX | XXX | XXX |
| EV/FCF | -94.8x | XXX | -34.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGlenmark Pharma's last 12 month revenue growth is 11%
Glenmark Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Glenmark Pharma's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Glenmark Pharma's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Glenmark Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 31% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Glenmark Pharma acquired XXX companies to date.
Last acquisition by Glenmark Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Glenmark Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Glenmark Pharma founded? | Glenmark Pharma was founded in 1977. |
| Where is Glenmark Pharma headquartered? | Glenmark Pharma is headquartered in India. |
| How many employees does Glenmark Pharma have? | As of today, Glenmark Pharma has 12.7K+ employees. |
| Who is the CEO of Glenmark Pharma? | Glenmark Pharma's CEO is Mr. Glenn Saldanha. |
| Is Glenmark Pharma publicy listed? | Yes, Glenmark Pharma is a public company listed on BOM. |
| What is the stock symbol of Glenmark Pharma? | Glenmark Pharma trades under 532296 ticker. |
| When did Glenmark Pharma go public? | Glenmark Pharma went public in 2000. |
| Who are competitors of Glenmark Pharma? | Similar companies to Glenmark Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Glenmark Pharma? | Glenmark Pharma's current market cap is $5.8B |
| What is the current revenue of Glenmark Pharma? | Glenmark Pharma's last 12 months revenue is $1.6B. |
| What is the current revenue growth of Glenmark Pharma? | Glenmark Pharma revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Glenmark Pharma? | Current revenue multiple of Glenmark Pharma is 3.7x. |
| Is Glenmark Pharma profitable? | Yes, Glenmark Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Glenmark Pharma? | Glenmark Pharma's last 12 months EBITDA is $289M. |
| What is Glenmark Pharma's EBITDA margin? | Glenmark Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Glenmark Pharma? | Current EBITDA multiple of Glenmark Pharma is 20.3x. |
| What is the current FCF of Glenmark Pharma? | Glenmark Pharma's last 12 months FCF is -$62.0M. |
| What is Glenmark Pharma's FCF margin? | Glenmark Pharma's last 12 months FCF margin is -4%. |
| What is the current EV/FCF multiple of Glenmark Pharma? | Current FCF multiple of Glenmark Pharma is -94.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
